27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
- Kite, a Gilead Sciences Inc company (NASDAQ:GILD), announced a global strategic collaboration to co-develop and co-commercialize Arcellx Inc's (NASDAQ:ACLX) lead late-stage product candidate, CART-ddBCMA, for relapsed or refractory multiple myeloma.
- Kite and Arcellx will jointly advance the CART-ddBCMA asset.
- Arcellx will receive an upfront payment of $225 million, a $100 million equity investment, and other potential contingent payments.
- The companies will share development, clinical trial, and commercialization costs for CART-ddBCMA and will jointly commercialize the product and split U.S. profits 50/50.
- Outside the U.S., Kite will commercialize the product.
- Arcellx also announced interim CART-ddBCMA Phase 1 results (October 31, 2022 cutoff date), demonstrating deep and durable responses.
- Of the 38 evaluable patients with a median follow-up of 15 months, a 100% overall response rate (ORR) was achieved in all patients.
- 27 of 38 (71%) evaluable patients achieved complete response (CR).
- CART-ddBCMA continues to be well-tolerated, showing no tissue-targeted toxicities and no cases of delayed neurotoxicity events or parkinsonian symptoms.
- The company also initiated a Phase 1 study evaluating the safety of ACLX-002 in adults with relapsed and/or refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS).
- The secondary objectives are to measure the anti-tumor activity and pharmacokinetics of both SparX-002 and ARC-T cells.
- Price Action: ACLX shares are up 22.5% at $26.57 on the last check Friday.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!